在非转移性鼻癌中预测存活率和选择辅助化疗的治疗反应调整的风险指数模型
Yang Liu1, Wenbin Yan2, Yupei Chen3
1Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
NPJ digital medicine
|September 1, 2025
概括
我们开发了响应适应的个性化风险指数 (RAIRI),以预测助剂化疗 (AC) 在鼻癌 (NPC) 中的益处. RAIRI准确地识别了哪些患者会和不会从AC中受益,从而实现了个性化治疗选择.
科学领域:
- 癌症学
- 生物统计学
- 医学成像
背景情况:
- 对癌症治疗的动态反应显著影响患者的结果.
- 准确的预后和治疗益处的预测对于有效的癌症管理至关重要.
研究的目的:
- 开发和验证响应适应的个性化风险指数 (RAIRI) 作为一个动态的预测工具.
- 确定RAIRI作为助剂化疗 (AC) 对鼻癌 (NPC) 的益处的预测生物标志物.
主要方法:
- 使用贝叶斯联合模型开发和验证RAIRI模型.
- 包括治疗前临床数据,长度无细胞爱斯坦巴尔病毒DNA和基于MRI的瘤回归测量.
- 在包括随机对照试验 (RCT) 在内的多组患者中验证了RAIRI.
主要成果:
- 与传统模型相比,RAIRI显示了准确的校准和更高的预测准确性.
- 在RCT队列中,RAIRI有效地发现了约70%的低风险患者没有从AC中受益.
- 通过RAIRI识别的高风险患者从AC中获得了实质性的益处.
结论:
- RAIRI是一个动态的多维模型,用于NPC的个性化风险评估.
- 通过提供实时更新的生存估计,RAIRI促进了辅助化疗的个性化选择.
- 这种方法支持精准医学,通过根据个体患者的反应优化AC治疗决策.
更多相关视频
04:09Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
Published on: October 10, 2018
8.3K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.2K
相关概念视频
Cancer Survival Analysis
448
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
448
Kaplan-Meier Approach
258
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
258
